Last reviewed · How we verify
Varenicline or bupropion
Varenicline and bupropion, developed by Yale University, are marketed drugs primarily indicated for smoking cessation. A key strength is the protection of their composition through a patent expiring in 2028. The primary risk is the lack of revenue data, which may affect investment and market strategy decisions.
At a glance
| Generic name | Varenicline or bupropion |
|---|---|
| Also known as | Varenicline Tartrate and bupropion |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Preoperative Smoking Cessation in Patients Undergoing Surgery (NA)
- Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening (NA)
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Metabolism-informed Care for Smoking Cessation (NA)
- A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV (PHASE4)
- Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial (PHASE4)
- Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use (NA)
- Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Varenicline or bupropion CI brief — competitive landscape report
- Varenicline or bupropion updates RSS · CI watch RSS
- Yale University portfolio CI